CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
A Study of Durvalumab and BA3011 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy
A Study of Durvalumab and BA3021 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied. Some of them are extremely rare, with only a few people diagnosed each year. Patients with these rare cancers have not had the same improvements in survival outcomes as those with more common cancers, largely because there has been less focus on research and the development and testing of new treatment options.
A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.
At the European Society For Medical Oncology (ESMO 21) Congress Dr. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial. The five-year data from the trail has confirmed the significant benefits in all outcomes. After surgery, two out of five patients treated with mFOLFIRINOX did not experience disease relapse compared to one out of five in those treated with gemcitabine.
The CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer study results were recently published in the Journal of Thoracic Oncology.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS More >>
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
J Clin Oncol , 2022Mayer EL;Fesl C;Hlauschek D;Garcia-Estevez L;Burstein HJ;Zdenkowski N;Wette V;Miller KD;Balic M;Mayer IA;Cameron D;Winer EP;Ponce Lorenzo JJ;Lake D;Pristauz-Telsnigg G;Haddad TC;Shepherd L;Iwata H;Goetz M;Cardoso F;Traina TA;Sabanathan D;Breitenstein U;Ackerl K;Metzger Filho O;Zehetner K;Solomon K;El-Abed S;Theall KP;Lu DR;Dueck A;Gnant M;DeMichele A;
J Clin Oncol , 2022Khan SA;Zhao F;Goldstein LJ;Cella D;Basik M;Golshan M;Julian TB;Pockaj BA;Lee CA;Razaq W;Sparano JA;Babiera GV;Dy IA;Jain S;Silverman P;Fisher CS;Tevaarwerk AJ;Wagner LI;Sledge GW;
J Clin Oncol , 2022Cheng E;Ou FS;Ma C;Spiegelman D;Zhang S;Zhou X;Bainter TM;Saltz LB;Niedzwiecki D;Mayer RJ;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Brown JC;Ng K;Gross CP;Meyerhardt JA;Fuchs CS;
Ann Oncol 33: 42 - 56, 2022Federico L;McGrail DJ;Bentebibel SE;Haymaker C;Ravelli A;Forget MA;Karpinets T;Jiang P;Reuben A;Negrao MV;Li J;Khairullah R;Zhang J;Weissferdt A;Vaporciyan AA;Antonoff MB;Walsh G;Lin SY;Futreal A;Wistuba I;Roth J;Byers LA;Gaudreau PO;Uraoka N;Cruz AF;Dejima H;Lazcano RN;Solis LM;Parra ER;Lee JJ;Swisher S;Cascone T;Heymach JV;Zhang J;Sepesi B;Gibbons DL;Bernatchez C;
Int J Cancer 150: 279 - 289, 2022Quintanilha JCF;Wang J;Sibley AB;Xu W;Espin-Garcia O;Jiang C;Etheridge AS;Ratain MJ;Lenz HJ;Bertagnolli M;Kindler HL;Dickler MN;Venook A;Liu G;Owzar K;Lin D;Innocenti F;
Pharmacogenetics and Genomics 31: 215 - 220, 2021Patel JN;Jiang C;Owzar K;Mulkey F;Luzum JA;Mamon HJ;Haller DG;Dragovich T;Alberts SR;Bjarnason G;Willet CG;Niedzwiecki D;Enzinger P;Ratain MJ;Fuchs C;McLeod HL;
Clinical Lymphoma Myeloma and Leukemia 21: 766 - 774, 2021Cheung MC;Mittmann N;Owen C;bdel-Samad N;Fraser GAM;Lam S;Crump M;Sperlich C;van der Jagt R;Prica A;Couban S;Woyach JA;Ruppert AS;Booth AM;Mandrekar SJ;McDonald G;Shepherd LE;Yen H;Chen BE;Hay AE;
